AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint

AVEO Oncology today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company ’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC).11/06/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news